Market Exclusive

Analyst Activity – Needham & Company LLC Reiterates Sell on ResMed (NYSE:RMD)

Analyst Ratings For ResMed (NYSE:RMD)

Today, Needham & Company LLC reiterated its Sell rating on ResMed (NYSE:RMD).

There are 4 sell ratings, 5 hold ratings, 2 buy ratings on the stock.

The current consensus rating on ResMed (NYSE:RMD) is Hold (Score: 1.82) with a consensus target price of $61.29 per share, a potential 20.90% downside.

Some recent analyst ratings include

Dividend information for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) pays an annual dividend of Community Ranking: with a yield of 1.70% and an average dividend growth of 14.50% based on a 3 Year Average.

Dividend History for ResMed (NYSE:RMD)

Recent Insider Trading Activity For ResMed (NYSE:RMD)
ResMed (NYSE:RMD) has insider ownership of 1.97% and institutional ownership of 60.65%.

Recent Trading Activity for ResMed (NYSE:RMD)
Shares of ResMed closed the previous trading session at 77.48 up +0.36 0.47% with 1,017,605 shares trading hands.

Exit mobile version